As filed with the Securities and Exchange Commission on February 27, 2019
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Intellia Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 36-4785571 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
40 Erie Street, Suite 130
Cambridge, Massachusetts (857) 285-6200
(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)
Intellia Therapeutics, Inc. 2015 Amended and Restated Stock Option and Incentive Plan
Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan
(Full title of the plans)
John Leonard, M.D.
President and Chief Executive Officer
40 Erie Street, Suite 130
Cambridge, Massachusetts
(857) 285-6200
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
| Arthur R. McGivern, Esq. William D. Collins, Esq. Goodwin Procter LLP 100 Northern Ave. Boston, Massachusetts 02210 (617) 570-1000 |
José E. Rivera, Esq. Executive Vice President, General Counsel Intellia Therapeutics, Inc. 40 Erie Street, Suite 130 Cambridge, Massachusetts (857) 285-6200 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
| Emerging growth company | ☐ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
| ||||||||
| Title of securities to be registered |
Amount to be registered (1) |
Proposed maximum offering price per share |
Proposed maximum aggregate offering price |
Amount of registration fee | ||||
| Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan |
876,090 shares (2) | $14.47 (4) | $12,677,022.30 (4) | $1,536.46 | ||||
| Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan |
3,504,363 shares (3) | $14.47 (4) | $50,708,132.61 (4) | $6,145.83 | ||||
|
| ||||||||
|
| ||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. |
| (2) | Represents an automatic increase to the number of shares available for issuance under the 2016 Employee Stock Purchase Plan (the “2016 ESPP”), of (i) 423,846 effective as of January 1, 2018 and (ii) 452,244 effective as of January 1, 2019. Shares available for issuance under the 2016 ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on May 6, 2016 (File No. 333-21200) and June 5, 2017 (File No. 333-218511). |
| (3) | Represents an automatic increase to the number of shares available for issuance under the Amended and Restated 2015 Stock Option and Incentive Plan (the “2015 Plan”), of (i) 1,695,384 effective as of January 1, 2018 and (ii) 1,808,979 effective as of January 1, 2019. Shares available for issuance under the 2015 Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on May 6, 2016 (File No. 333-21200) and June 5, 2017 (File No. 333-218511). |
| (4) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $14.47, the average of the high and low price of the registrant’s Common Stock as reported on the NASDAQ Global Market on February 26, 2019. |
Statement of Incorporation by Reference
This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 3,504,363 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s Amended and Restated 2015 Stock Option and Incentive Plan and (ii) an additional 876,090 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s 2016 Employee Stock Purchase Plan. This Registration Statement incorporates by reference the contents of the registration statement on Form S-8, File No. 333-211200, filed by the Registrant on May 6, 2016, and the registration relating to the Registrant’s Amended and Restated 2015 Stock Option and Incentive Plan and 2016 Employee Stock Purchase Plan pursuant to General Instruction E.
Part II
Information Required in the Registration Statement
Item 8. Exhibits.
See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 27th day of February, 2019.
| INTELLIA THERAPEUTICS, INC. | ||
| By: |
/s/ John Leonard | |
| John Leonard, M.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of John Leonard, M.D., José E. Rivera, J.D. and Glenn Goddard as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.
| Name |
Title |
Date | ||
| /s/ John Leonard John Leonard, M.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
February 27, 2019 | ||
| /s/ Glenn Goddard Glenn Goddard |
Executive Vice President, Chief Financial Officer (Principal Financial and Principal Accounting Officer) |
February 27, 2019 | ||
| /s/ Fred Cohen Fred Cohen, M.D., D.Phil. |
Director |
February 27, 2019 | ||
| /s/ Caroline Dorsa Caroline Dorsa |
Director |
February 27, 2019 | ||
| /s/ Jean François Formela Jean François Formela, M.D. |
Director |
February 27, 2019 | ||
| /s/ Jesse Goodman Jesse Goodman, M.D. |
Director |
February 27, 2019 | ||
| /s/ Perry Karsen Perry Karsen |
Director |
February 27, 2019 | ||
| /s/ Frank Verwiel Frank Verwiel, M.D. |
Director |
February 27, 2019 | ||